Opus Genetics
IRD
50 hedge funds and large institutions have $11.3M invested in Opus Genetics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 11 closing their positions.
3,525% more call options, than puts
Call options by funds: $435K | Put options by funds: $12K
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
2% more funds holding
Funds holding: 49 → 50 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.22% less ownership
Funds ownership: 17.87% → 16.65% (-1.2%)
10% less capital invested
Capital invested by funds: $12.6M → $11.3M (-$1.23M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$390K |
| 2 |
Millennium Management
New York
|
+$254K |
| 3 |
Morgan Stanley
New York
|
+$245K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$204K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$759K |
| 2 |
RB
Richmond Brothers
Jackson,
Michigan
|
-$341K |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$189K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$165K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$99.9K |
IRD Hedge Fund Activity: Q4 2023 in Review
50 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q4 2023, worth a combined $11.3M — down 9.8% from $12.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new IRD positions and 11 closed out — a net gain of 1 holder — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Bridgeway Capital Management, adding an estimated $390K. The largest seller was Rice Hall James & Associates, cutting an estimated $759K.
- 50 institutional investors held Opus Genetics (IRD) as of Q4 2023, up from 49 in Q3 2023.
- Funds reported $11.3M of Opus Genetics stock for Q4 2023, down 9.8% quarter-over-quarter.
- 12 funds opened new Opus Genetics positions in Q4 2023 and 11 closed out, a net change of +1 holder.
- The largest Opus Genetics buyer in Q4 2023 was Bridgeway Capital Management, an estimated $390K added.
- The largest Opus Genetics seller in Q4 2023 was Rice Hall James & Associates, an estimated $759K sold.
Based on aggregated 13F filings for Q4 2023.